Portfolio Update: Glycotest and ProAxsis

This is a capital shuffle, not proof of business growth or profitability.

What the company is saying

EMV Capital plc is presenting a narrative of successful portfolio management, emphasizing its ability to raise capital and restructure holdings in its healthcare and biotech investments, specifically Glycotest, Inc. and ProAxsis Limited. The company wants investors to believe that these fundraising events and capital reorganizations directly translate into increased value and future upside. The announcement highlights the closure of a $3.22 million fundraising round for Glycotest, a 24.3% uplift in its fair value to £13.7 million, and a 191% increase in third-party assets under management, all framed as evidence of strong portfolio momentum. For ProAxsis, the focus is on a share capital reorganisation to enable EIS qualification, a proposed £1.0 million fundraising, and a new loan agreement with AB Group Limited, all intended to signal ongoing financial support and structural readiness for growth. The language is confident and upbeat, repeatedly referencing anticipated increases, successful closings, and future fundraising headroom, but it avoids any discussion of revenue, profitability, or operational milestones. The announcement is detailed about the mechanics of the transactions—percentages, fair values, and loan terms—but omits any operational or financial performance data for the underlying businesses. Notable individuals include Dr Ilian Iliev, CEO of EMV Capital plc, who is excluded from certain board decisions due to a concert party relationship with Melvin Lawson, a related party with a 14.43% stake in EMV Capital; this signals internal governance awareness but also highlights potential conflicts of interest. The overall communication style is technical and transactional, designed to reassure investors of management’s deal-making prowess and the portfolio’s upward trajectory, while steering attention away from the lack of operational evidence.

What the data suggests

The disclosed numbers confirm that Glycotest, Inc. closed a first tranche fundraising of approximately $3.22 million, split between $1.05 million in new cash and $2.17 million from loan conversions. EMV Capital converted $0.97 million of its own convertible loan, leaving a $0.37 million balance, and now holds 48.67% of Glycotest’s equity (fully diluted, excluding the remaining loan). The post-investment fair value of Glycotest is stated as £13.7 million, up from £11.0 million at 31 December 2025—a 24.3% increase. Third-party assets under management in Glycotest are now valued at £5.2 million, up from £1.8 million, a 191% increase. For ProAxsis, EMV Capital’s equity holding is 49.87% post-reorganisation, with a proposed fundraising of up to £1.0 million (including £0.9 million in cash and £0.1 million in liability conversion), and a new loan agreement of £525,000 at 10% interest, repayable by August 2027 or 2028. However, there is no disclosure of revenue, profit/loss, cash burn, or operational KPIs for either company. The fair value uplift for Glycotest is directly tied to the fundraising event, not to any underlying business improvement. For ProAxsis, the fair value is stated as unchanged at £8.0 million, but no post-fundraising or current valuation is provided. The data is detailed on capital structure and transaction mechanics but omits the financial health and performance of the portfolio companies. An independent analyst would conclude that while the capital events are real and the numbers reconcile, there is no evidence that these transactions are translating into sustainable business growth or profitability.

Analysis

The announcement is upbeat, highlighting successful fundraising rounds and increases in fair value for Glycotest, as well as structural changes and anticipated fundraising for ProAxsis. However, the progress is limited to capital events—there is no disclosure of revenue, profit/loss, or operational performance for either company. Many claims, especially regarding future fundraising, share option schemes, and increases in third-party assets under management, are forward-looking and not yet realised. The capital outlays are significant relative to the companies' size, and the benefits (such as increased value or operational milestones) are not immediate but expected over the coming months to years. The language inflates the signal by focusing on fair value uplifts and anticipated events without supporting operational or profitability data. The data supports that fundraising has occurred and equity positions have changed, but does not evidence underlying business improvement or value creation beyond these transactions.

Risk flags

• ●Operational opacity: There is no disclosure of revenue, profit/loss, or operational performance for Glycotest or ProAxsis. This lack of transparency makes it impossible for investors to assess whether the capital raised is being deployed effectively or if the businesses are progressing toward commercial viability.
• ●Capital intensity with delayed payoff: Both Glycotest and ProAxsis are raising significant sums relative to their size—$3.22 million and up to £1.0 million, respectively—yet the benefits are framed as future fair value uplifts or anticipated operational milestones, not immediate returns. This pattern is typical of capital-intensive ventures with long, uncertain payback periods.
• ●High proportion of forward-looking statements: Nearly half of the key claims are forward-looking, including anticipated fundraisings, share option schemes, and increases in assets under management. These are not yet realised and depend on successful execution and market conditions.
• ●Related party transaction risk: The loan agreement with AB Group Limited, a related party with a 14.43% stake in EMV Capital, introduces potential conflicts of interest. While the board claims fairness, there is no independent valuation or external validation of the terms.
• ●Accounting and control transition risk: The planned deconsolidation of Glycotest and ProAxsis as of 30 June 2026 will change how these holdings are reported, potentially reducing transparency and making it harder for investors to track performance or influence outcomes.
• ●Lack of operational milestones: The announcement is silent on clinical, regulatory, or commercial progress for either company. Without such milestones, investors have no way to gauge whether the capital raised will translate into real-world value.
• ●Geographic and regulatory complexity: The companies operate across multiple jurisdictions (Georgia, United Kingdom), which can introduce additional legal, tax, and compliance risks, especially as structures change and new investors are brought in.
• ●Valuation uplift based on capital events, not business fundamentals: The reported increases in fair value are a direct result of fundraising and loan conversions, not improvements in underlying business performance. This creates a risk that future valuations may not be sustainable if operational progress does not follow.

Bottom line

For investors, this announcement is a detailed update on capital events and structural changes within EMV Capital plc’s portfolio, but it does not provide evidence of underlying business growth or profitability. The fair value uplifts for Glycotest are entirely a function of new money coming in and loan conversions, not operational achievements or improved financial performance. ProAxsis’s situation is even less clear, with no updated fair value or operational data disclosed post-fundraising. The involvement of related parties in financing arrangements adds governance complexity and potential conflicts of interest, despite board assurances of fairness. To materially change this assessment, the company would need to disclose revenue, EBITDA, net income, cash burn, and clear operational milestones for both Glycotest and ProAxsis. Investors should watch for actual completion of the proposed ProAxsis fundraising, any updates on clinical or commercial progress, and the impact of deconsolidation on transparency and reporting. At present, the signal is weakly positive—there is evidence of deal-making and capital inflow, but no proof that these moves are creating sustainable value. This announcement is worth monitoring for future developments, but not acting on as a standalone investment catalyst. The single most important takeaway is that capital events alone do not guarantee business success; without operational progress, these transactions may simply reshuffle ownership without creating real value.

Announcement summary

(AIM: EMVC) EMV Capital plc announced that Glycotest, Inc. has successfully closed a first tranche fundraising totaling c.$3.22 million of equity investment, including c.$1.05 million of cash and c.$2.17 million from the conversion of certain existing loans. Following this, the Group's total equity holding in Glycotest is 48.67 per cent. (fully diluted but not including the outstanding balance of the CLA), equating to a post-investment fair value of £13.7 million, a c.24.3 per cent. increase compared to £11.0 million at 31 December 2025. Glycotest has headroom to close additional funding up to c.$1.95 million in further rounds within 120 days of the first closing. ProAxsis Limited has completed a share capital reorganisation and is launching a proposed fundraising of up to £1.0 million, including up to c.£0.9 million of cash and £0.1 million of liabilities converting under a pre-agreed arrangement with Randox Laboratories. The Group's total equity holding in ProAxsis is 49.87 per cent. of the issued share capital, and ProAxsis has entered into a loan agreement with AB Group Limited totalling c.£525,000, with repayment extended to 4 August 2027 or 4 August 2028 if agreed. The Group intends to deconsolidate each of Glycotest and ProAxsis with effect from 30 June 2026 and to account for its retained interests as investments in associates under IAS 28.

Disagree with this article?